FindTrial
Sign In

The aoran newborn study: an observational real-world clinical study of central nervous system lymphoma (CNSL)

The aoran newborn study: an observational real-world clinical study of central nervous system lymphoma (CNSL)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100045388
Enrollment
Unknown
Registered
2021-04-14
Start date
2021-05-01
Completion date
Unknown
Last updated
2021-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central nervous system lymphoma (CNSL)

Interventions

Intervention group:Stem cell transplantation + posttransplant maintenance therapy with orelabrutinib

Sponsors

Liu Zhigang
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 70 Years

Inclusion criteria

Inclusion criteria: 1. Chinese subjects = 70g/L; 4. Neutral lobulated grains >= 1.5 x 10^9/L; 5. Platelet >= 150 x10^9/L; 6. ECOG <= 2 points; 7. Subjects must sign the informed consent form (ICF) to indicate that they understand the purpose and procedures of the study and are willing to participate in the study. Informed consent must be obtained before commencing any test or procedure that is relevant to any study but is not part of the standard treatment for the subject's disease; 8. Willing and able to follow the taboos and restrictions set out in this program.

Exclusion criteria

Exclusion criteria: 1. Increased creatinine; 2. Positive urine protein; 3. Previous cerebral infarction, myocardial infarction and other thrombotic events; 4. Cardiac function >= Grade 3; 5. Past serious digestive system diseases.

Design outcomes

Primary

MeasureTime frame
Overall survival (OS);Progression-free survival (PFS);The curative effect;—

Countries

China

Contacts

Public ContactLiu Zhigang

West China Hospital, Sichuan University

hxdoctorliu@126.com+86 18980606798

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026